Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area

Figures & data

Figure 1. Study flowchart. TT: tailored therapy; BQT: bismuth quadruple therapy; ITT: intention-to-treat; mITT: modified intention-to-treat; PP: per protocol.

Figure 2. Flowchart of patients in the tailored therapy group. TT: tailored therapy; ITT: intention-to-treat; mITT: modified intention-to-treat; PP: per protocol; BQT: bismuth quadruple therapy.

Table 1. Basic characteristics of patients in the two study groups.

	TT group	BQT group	p Value
No. of patients	178	182
Male gender, n (%)	125 (70.22)	110 (60.44)	.051
Age, mean ± SD (years)	56.9 (12.52)	57.9 (11.59)	.670
Indication, n (%)
Peptic ulcer	62 (34.83)	72 (39.56)	.445
Stomach cancer	46 (25.84)	32 (17.58)
Gastric adenoma	23 (12.92)	23 (12.63)
Gastritis	40 (22.47)	46 (25.27)
Others	7 (3.93)	8 (3.39)

TT: tailored therapy; BQT: bismuth quadruple therapy.

Table 2. Helicobacter pylori eradication efficacies in the two groups.

	TT group		BQT group		p Value
ITT eradication rates, n (%)	118/178	(66.3)	142/182	(78.0)	.013
Modified ITT eradication rates, n (%)	118/147	(80.3)	142/161	(88.2)	.055
PP eradication rates, n (%)	118/145	(81.4)	142/160	(88.8)	.067

TT: tailored therapy; BQT: bismuth quadruple therapy; ITT: intention-to-treat; mITT: modified intention-to-treat; PP: per protocol.

Table 3. Compliance and adverse events in the two groups.

	TT group	BQT group	p Value
Compliance, n (%)	145/147 (98.6)	160/161(99.4)	.509
Adverse events, n (%)
None	136 (93.2)	145 (90.1)	.564
Bitter taste	5 (3.42)	7 (4.35)
Nausea/vomiting	3 (2.05)	3 (1.86)
Diarrhea	2 (1.37)	2 (1.24)
Headache	0 (0.00)	1 (0.62)
Others	0 (0.00)	3 (1.86)

Data availability statement

All data generated or analyzed during this study are included in this published article.